{"id":"vorolanib-tablets-everolimus","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Anemia"},{"rate":"5-10%","effect":"Thrombocytopenia"},{"rate":"5-10%","effect":"Neutropenia"},{"rate":"5-10%","effect":"Leukopenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Vorolanib works by inhibiting the VEGF signaling pathway, which is involved in angiogenesis and tumor growth. Everolimus, on the other hand, inhibits the mTOR pathway, which is involved in cell proliferation and survival.","oneSentence":"Vorolanib is a tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFRs), and Everolimus is an mTOR inhibitor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:40:46.742Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Renal cell carcinoma"}]},"trialDetails":[{"nctId":"NCT07165418","phase":"PHASE3","title":"A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma Who Have Progressed After Treatment With Immunotherapy Monotherapy or in Combination With TKI","status":"NOT_YET_RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2025-09-25","conditions":"Renal Cell Carcinoma (RCC)","enrollment":116},{"nctId":"NCT03095040","phase":"PHASE3","title":"CM082 Combined With Everolimus in Chinese Patients With Metastatic Renal Cell Carcinoma","status":"UNKNOWN","sponsor":"AnewPharma","startDate":"2016-12-16","conditions":"Renal Cell Cancer Metastatic","enrollment":390},{"nctId":"NCT02577458","phase":"PHASE1","title":"Study of the Combination of CM082 With Everolimus in Patients With mRCC","status":"UNKNOWN","sponsor":"AnewPharma","startDate":"2015-09","conditions":"Renal Cell Carcinoma Recurrent","enrollment":18}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Vorolanib Tablets+Everolimus","genericName":"Vorolanib Tablets+Everolimus","companyName":"Peking University Cancer Hospital & Institute","companyId":"peking-university-cancer-hospital-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Vorolanib tablets, when combined with everolimus, are being studied for the treatment of metastatic renal cell cancer, renal cell carcinoma recurrent, and renal cell carcinoma. Everolimus is a small molecule that acts as an inhibitor of the FK506-binding protein 1A, which is involved in cell signaling pathways.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}